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The use of the Angioseal device for femoral artery
closure
Alan Abando, MD, Douglas Hood, MD, Fred Weaver, MD, and Steven Katz, MD, Pasadena Calif
Background: As vascular surgeons perform increasing numbers of percutaneous catheter–based procedures, they will need
to become familiar with varying methods of femoral artery closure. Few studies on closure devices have included
significant numbers of patients with peripheral arterial disease. It is the purpose of this study to determine whether the
Angioseal device (St. Jude Medical) is a satisfactory method of achieving femoral artery puncture site hemostasis in these
patients.
Methods: The records of all patients undergoing Angioseal closure of femoral artery puncture by a single vascular surgeon
were reviewed. Indication, type of intervention, and size of the vascular sheath employed were recorded. Times to
mobilization and discharge were determined. Patients were seen before discharge and 1, 4, and 12 weeks after the
procedure, and at 3- month intervals thereafter. Complications including hemorrhage, pseudoaneurysm, infection, and
vessel occlusion were noted.
Results: Between February 1, 2002, and August 31, 2003, 220 Angioseal collagen plugs were deployed in 188 patients.
Attempts were made to deploy Angioseal devices in 92% of patients undergoing percutaneous procedures during this time
period. One hundred forty-four procedures were diagnostic and 74 procedures included 76 therapeutic interventions.
One hundred forty-four 5F sheaths, 47 6F sheaths, and 29 7F sheaths were employed during the procedures. Time to
mobilization and discharge was 58  19 minutes and 102  31 minutes in patients undergoing diagnostic studies, 68 
22 minutes and 146 42 minutes following interventions using 6F sheaths, and 127 18 minutes and 219 37 minutes
when interventions were performed using 7F sheaths. No patient developed a major hematoma or infection following the
use of an Angioseal. There were 2 complications related to device deployment. One patient developed a 1.4-cm false
aneurysm at the femoral artery puncture site that resolved spontaneously. A second patient required operation for vessel
occlusion when an Angioseal was deployed in a markedly diseased femoral artery. These adverse events occurred early in
our experience.
Conclusions: The Angioseal provides a secure method of achieving hemostasis following femoral artery puncture. It is easy
to deploy, has a high level of patient satisfaction, and allows for early ambulation and hospital discharge. When simple
guidelines are observed, the device can be safely used in the great majority of patients with peripheral vascular disease. It
offers considerable advantages over the traditional method of manual compression. (J Vasc Surg 2004;40:287-90.)Puncture site complications following femoral artery
catheterization remain a significant source of patient mor-
bidity.1,2 Manual compression has been the traditional
method of achieving hemostasis following angiographic
procedures. Using this technique, access site complications
have ranged from 1% to 5% and have included bleeding,
pseudoaneurysm formation, and vessel occlusion. Groin
compression must be maintained for 10 to 20 minutes,
causes significant patient discomfort, and requires pro-
longed bed rest. These considerations have led to a great
deal of interest in alternate methods of achieving hemosta-
sis at the site of femoral artery puncture.
Devices have been designed to enhance femoral com-
pression. These have included clamps and inflatable devic-
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backs associated with groin compression. In recent years,
vascular closure devices that replace rather than augment
manual compression have been developed. The most com-
monly used devices include implantable collagen plugs and
percutaneous suture devices.5
Vascular surgeons performing catheter- based proce-
dures have been reluctant to abandon manual compression
as their primary means of achieving access site hemostasis.
Indeed, reports in the vascular literature have been largely
limited to complications of these devices rather than their
utility.6-8 However, as vascular surgeons perform larger
numbers of percutaneous interventions, it will become
increasingly important for them to become familiar with
the various methods of femoral artery closure. It is the
purpose of this study to determine whether the Angioseal
implantable collagen plug (St. Jude Medical, St. Paul,
Minn) is a satisfactory method of femoral artery closure
following transcatheter procedures in patients with periph-
eral arterial disease.
METHODS
The records of all patients undergoing Angioseal clo-
sure of femoral artery puncture sites performed by a single287
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cases. Patient age, sex, demographics, and the use of anti-
coagulants and antiplatelet agents were recorded. Proce-
dures were not performed in patients on warfarin if the
international normalized ratio exceeded 2.0. Size of the
vascular sheath employed, type of procedure performed,
and indication for arteriography was noted.
All procedures were performed in the angiography
suite. Patients were prepped with a 5-minute scrub of liquid
betadine. Patients with iodine allergy were scrubbed with
chlorhexidene. Femoral artery cannulation was achieved
with 21-gauge entry needles using micropuncture tech-
nique. Diagnostic studies were performed using 5F sys-
tems, and 6F and 7F sheaths were employed for interven-
tions. Patients undergoing angioplasty were given 5000 U
of heparin prior to balloon dilatation or stent placement.
The heparin was not reversed at the conclusion of the
intervention. Periprocedural antibiotics were not used. The
Angioseal was deployed in native common femoral arteries
greater than 5 mm when there was found to be no luminal
narrowing of 40% or greater within 5 mm of the puncture
site. The 5-mm measurement was based on the inside
diameter of the vessel as measured from films showing
minimal magnification. Measurements of arterial size and
luminal narrowing were performed from printed films
when indicated. The decision not to deploy an Angioseal
was made solely on angiographic criteria. An ileofemoral
angiogram was performed in all cases. Closure devices were
placed immediately following the conclusion of each pro-
cedure. Six-French Angioseal devices were deployed after
the use of 5F and 6F sheaths. The 8F Angioseal device was
used to seal puncture sites created by 7F sheaths. Patients
were placed at bedrest for at least 30 minutes after use of the
6F device and 90 minutes following use of the 8F device per
the product representative recommendations.
Time to mobilization was defined as the time from
device deployment until recovery room personnel noted
that patients had been removed from bedrest and allowed
to ambulate or assume their baseline level of activity. Time
to discharge was defined as the time from device deploy-
ment until patients were evaluated by a physician and the
order to discharge given. At this time, patients were trans-
ferred from recovery room level of care to outpatient status.
Patients were examined for access site complication and
success of intervention before discharge from the hospital;
at 1, 4, and 12 weeks after the procedure; and at 3-month
intervals thereafter. Complications including infection re-
quiring antibiotic administration, pseudoaneurysm forma-
tion, or vessel compromise were recorded. Bleeding epi-
sodes causing a hematoma greater than 6 cm and a decrease
in hemoglobin of more than 1 g, as well as those requiring
transfusion or necessitating operation, were noted.
RESULTS
Between February 1, 2002, and July 31, 2003, 220
Angioseal devices were deployed in 188 patients. There
were 104 males and 84 females whose age ranged from 48
to 94 years (mean, 69 years). Thirty-eight percent of pa-tients had diabetes, 42% had hypertension, 36% had coro-
nary artery disease, and 44% smoked more than 20 ciga-
rettes per day. Sixty-six percent of patients were taking
antiplatelet agents and 24% were on warfarin anticoagula-
tion. An additional 19 patients undergoing femoral artery
catheterizations were treated with manual compression
when they were found to have 40% luminal reduction at the
site of puncture (17 patients) or when the puncture was at
the femoral bifurcation (2 patients). Patient follow-up
ranged from 1 to 18 months (mean, 7.2 months).
One hundred forty-four procedures were diagnostic
and 74 procedures included 76 therapeutic interventions.
Indications for procedure included lower extremity isch-
emia in 72% of patients, cerebrovascular insufficiency in
24% of patients, and visceral ischemia in 4% of patients. One
hundred forty-four 5F sheaths, 47 6F sheaths, and 29 7F
sheaths were employed during the procedures. Of the 76
interventions, 49 were performed on the iliac arteries, 27
on the superficial femoral and popliteal arteries. Twenty-
five angioplasties were performed and an additional 51
procedures included intravascular stents. All but 3 of the
Angioseal devices were successfully deployed. The failures
occurred when the intravascular anchor failed to engage the
arterial wall and the Angioseal was displaced before being
properly positioned. In this instance, groin hemostasis was
achieved by manual compression. All failures were in the 6F
device. Time to mobilization and discharge was 58  19
minutes and 102  31 minutes in patients undergoing
diagnostic studies, 68 22 minutes and 146 42 minutes
following interventions using 6F sheaths, and 127  18
minutes and 219  37 minutes when interventions were
performed using 7F sheaths.
There were no significant bleeding complications or
infections in patients undergoing femoral artery closure
with the Angioseal. Two patients suffered complications
related to the use of the closure device. One patient devel-
oped a 1.4-cm pseudoaneurysm of the femoral artery,
which resolved spontaneously. A second patient developed
a common femoral artery occlusion with ischemic rest pain
24 hours after an Angioseal was deployed in a markedly
diseased vessel. The vessel occlusion was caused by the
anchor lifting up an intimal plaque that resulted in vessel
occlusion. The puncture was not subintimal and the colla-
gen plug was found to be extraluminal. This patient under-
went a femoral endarterectomy and patch with complete
resolution of the limb ischemia. Both of these complica-
tions occurred following diagnostic angiograms. Three pa-
tients expired of unrelated causes 1, 4, and 7 months after
the procedure. An additional 2 patients were lost to follow
up 9 and 11 months after their procedure and were doing
well at the time of their last visit. Of the patients undergo-
ing manual compression, 1 developed a major hematoma
requiring admission to the hospital and transfusion. The
remaining 18 did well without complication. The only
patient requiring unintended re-admission to the hospital
within 30 days of a procedure was the previously mentioned
patient with femoral artery occlusion.
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In 1951, Seldinger9 introduced a technique that per-
mitted percutaneous access to the arterial tree. Three de-
cades later, the introduction of vascular sheaths allowed for
repetitive atraumatic vessel cannulation.10 During this
time, manual compression remained the only method of
achieving hemostasis following arterial puncture. In the
1990s the first generation of arterial closure devices was
introduced.11-13 These devices were relatively unsophisti-
cated and were plagued by significant complication rates.14
This led many interventionalists to abandon their use. In
recent years, advances in design have addressed many of the
problems associated with the early closure devices.15 Before
supplanting manual compression as the desired method of
achieving puncture site hemostasis, closure devices ideally
should be safe, be easy to deploy, and demonstrate benefits
such as increased patient comfort as well as early ambula-
tion and hospital discharge.
The Angioseal device was introduced in Europe in
1994. The original design has undergone several modifica-
tions allowing for easier and more consistent deployment.
The device consists of an anchor composed of a polylactide
and polyglycolide polymer, a collagen plug, and suture
contained within a special carrier system.16 When inserted,
it achieves hemostasis by compressing the arterial puncture
site between the anchor and the collagen plug. The An-
gioseal is an extremely simple device to master, can consis-
tently be deployed within 1 minute, and is completely
bioabsorbable. Although not recommended, vessels previ-
ously sealed with this device can safely be re-entered within
1 to 7 days.17
Hemostasis has been successfully obtained by using the
Angioseal in 95% to 100% of cases.18 In addition, compli-
cations such as infection, hemorrhage, and vessel occlusion
have been uncommon, ranging from 0.5 to 1.9%.19,20
These adverse events can be minimized by adherence to a
few simple guidelines. The use of 21-gauge micropuncture
entry needles will minimize the consequences of double
wall puncture. An Angioseal should not be deployed if the
arterial puncture site is above the inguinal ligament or
below the femoral bifurcation, if the vessel is diseased, or if
the artery is less than 5-mm in diameter. We routinely
perform ileofemoral arteriography before placing the An-
gioseal device. If the common femoral artery is more than
minimally diseased or if there is a question of vessel size,
nonmagnified print films are made and vessel diameter and
degree of luminal compromise measured. We consider a
vessel diameter less than 5 mm or luminal compromise of
40% or more within 5 mm of the puncture site as absolute
contraindications to the use of an Angioseal, while lesser
degrees of femoral artery stenosis should be considered as a
relative contraindication to device deployment. The only
complication in our series requiring operation occurred
very early in our experience, before the previously men-
tioned guidelines were adopted, when a device was de-
ployed in a vessel whose extent of occlusive disease was not
appreciated. In our last 170 cases, we have had no device-related complications. In our experience, infection has not
been a problem following Angioseal implantation. In addi-
tion, we have not had any intravascular stent infections even
though prophylactic antibiotics were not employed.
The use of the Angioseal closure device has allowed us
to significantly alter the clinical pathway of patients under-
going transcatheter diagnostic and interventional proce-
dures. In the past, puncture site hemostasis was achieved by
10 to 20 minutes of groin compression performed by
physicians or technologists. Arterial sheaths were not re-
moved until activated clotting times had normalized. Pa-
tients were maintained at bed rest for 4 to 6 hours and often
admitted to the hospital following percutaneous interven-
tions. Since the introduction of the Angioseal, no groin
compression has been needed, sheaths are removed imme-
diately following the procedure, and patients are ambulated
within 1 hour of placement of the 6F device and within 3
hours after placement of the 8F device. In our practice,
hospital admission following peripheral catheter-based in-
terventions has become a rarity, but we realize that patients
undergoing visceral or cerebral angioplasty may require
longer periods of observation. Our institutional cost for an
Angioseal is $215. In our hospital the cost for recovering a
patient following angiography is $285 per hour and an
overnight nonmonitored surgical bed (23-hour stay) is an
additional $1600. When manual compression is used to
achieve puncture site hemostasis, a number of standard
protocols including our own require a minimum of 4 hours
of bed rest following diagnostic studies performed with 5F
sheaths and a minimum of 6 hours of bed rest when larger
sheaths are used for therapeutic interventions.21 If one
assumes immediate discharge following mobilization in
patients undergoing manual compression, our data would
suggest that use of the Angioseal provides an average
per-patient savings of $440 for diagnostic angiograms em-
ploying 5F sheaths, $802 for interventions performed
through 6F sheaths, and $455 for interventions using 7F
sheaths. Of even more importance, the use of closure
devices has decreased the turnaround time and improved
the efficiency and productivity of the personnel in our
interventional suite. Early ambulation, rapid recovery time,
and decreased discomfort have led to a very high level of
patient satisfaction.
We conclude that the Angioseal provides an effective
means of femoral artery puncture site closure. It is easy to
deploy, has a high degree of patient acceptance, and allows
for early ambulation and hospital discharge. When simple
guidelines are observed, the device can be safely used in the
great majority of patients with peripheral arterial disease
with few infectious or occlusive complications. It offers a
number of advantages over the traditional method of man-
ual groin compression and we believe it is the preferred
means of achieving femoral access site hemostasis following
catheter-based procedures.
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